Amgen Inc. $AMGN Stock Sold by Beutel Goodman & Co Ltd.

Posted by Geri Gentry on Nov 10th, 2026

Beutel Goodman & Co Ltd. trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 35.5% in the third quarter, Holdings Channel reports. The institutional investor owned 335,540 shares of the medical research company’s stock after selling 185,037 shares during the period. Beutel Goodman & Co Ltd.’s holdings in Amgen were worth $141,433,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the stock. Pinion Investment Advisors LLC acquired a new stake in Amgen during the third quarter worth about $207,000. Leuthold Group LLC increased its holdings in Amgen by 9.2% in the 3rd quarter. Leuthold Group LLC now owns 22,409 shares of the medical research company’s stock valued at $9,446,000 after buying an additional 1,897 shares during the period. Fulcrum Asset Management LLP raised its position in shares of Amgen by 65.5% in the 3rd quarter. Fulcrum Asset Management LLP now owns 4,428 shares of the medical research company’s stock valued at $1,876,000 after buying an additional 1,752 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Amgen by 16.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 112,799 shares of the medical research company’s stock valued at $45,940,000 after buying an additional 16,327 shares in the last quarter. Finally, Beverly Hills Private Wealth LLC raised its position in shares of Amgen by 2.6% in the 3rd quarter. Beverly Hills Private Wealth LLC now owns 2,399 shares of the medical research company’s stock valued at $1,011,000 after buying an additional 60 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.85% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently issued reports on AMGN shares. Oppenheimer reiterated an “outperform” rating on shares of Amgen in a research report on Friday, October 23rd. The Goldman Sachs Group boosted their price objective on shares of Amgen from $481.00 to $536.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Cantor Fitzgerald boosted their price objective on shares of Amgen from $440.00 to $465.00 and gave the company a “neutral” rating in a research report on Wednesday, November 4th. TD Cowen upped their target price on Amgen from $452.00 to $531.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Finally, Scotiabank raised their target price on Amgen from $500.00 to $530.00 and gave the company a “sector outperform” rating in a report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Amgen has a consensus rating of “Hold” and an average price target of $422.76.

Get Our Latest Report on AMGN

Amgen Stock Up 1.0%

AMGN stock opened at $465.23 on Tuesday. The stock has a market capitalization of $251.52 billion, a P/E ratio of 20.64, a price-to-earnings-growth ratio of 3.47 and a beta of 0.43. The company has a current ratio of 1.48, a quick ratio of 1.13 and a debt-to-equity ratio of 3.60. Amgen Inc. has a 12 month low of $312.39 and a 12 month high of $483.99. The firm has a 50-day moving average price of $423.08 and a 200-day moving average price of $378.80.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The company had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the company posted $5.64 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 23.33 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 annualized dividend and a yield of 2.2%. Amgen’s dividend payout ratio is presently 58.47%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

Positive Sentiment: New AHA 2026 data reinforced Repatha’s potential: an analysis found it cost-effective for high-risk patients without a prior heart attack or stroke, while a separate long-term analysis associated treatment with a 29% lower risk of major cardiovascular events in patients with ASCVD. The findings could support wider use, though the reported analyses do not guarantee future sales growth. Article: New Repatha data at AHA 2026
Positive Sentiment: Amgen is heading into ACR week with a dazodalibep update expected November 11, creating a near-term clinical catalyst for its pipeline. The article headline does not specify the results, so the update’s impact will depend on the data. Article: Amgen stock heads into ACR week with dazodalibep update
Positive Sentiment: An article highlighted experimental obesity drug MariTide’s potential to reduce dosing from 52 injections a year to four. If borne out in clinical development, less frequent dosing could be a competitive advantage; the drug remains experimental. Article: Amgen’s new drug could mean fewer shots for obesity patients
Neutral Sentiment: Amgen shares rose in Monday trading but underperformed the broader market, indicating the move was not as strong as the overall market’s. Article: Amgen stock rises Monday, still underperforms market
Negative Sentiment: ETFs were net sellers of $68.5 million of AMGN on November 5, a potential near-term supply headwind, although 51 funds bought shares and 20 sold. Article: ETFs are net sellers of Amgen

About Amgen

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.